Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France

Supportive Care in Cancer

Volumn 24, Issue 1, 2016, Pages 67-75

  Toledano, Alain ^a   Luporsi, Elisabeth ^b   Morere, Jean François ^c   Scotté, Florian ^d   Laribi, Kamel ^e   Barrière, Jérôme ^f   Huot Marchand, Philippe ^g   Duvillié, Ladan ^h   Concas, Victor Hugo ^h   Bugat, Roland ⁱ  

^a AMERICAN HOSPITAL OF PARIS   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c AVICENNE HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e CENTRE HOSPITALIER DU MANS   (France)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g ICTA PM   (France)

^h Vifor (International) Inc   (Switzerland)

ⁱ INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Anaemia; Chemotherapy induced anaemia; Erythropoiesis stimulating agent; Ferric carboxymaltose; Haemoglobin; Intravenous; Iron; Iron deficiency

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; ANTINEOPLASTIC AGENT; FERRIC ION; IRON; MALTOSE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CONSTIPATION; DYSGEUSIA; FEMALE; FERRITIN BLOOD LEVEL; FRANCE; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOPHOSPHATEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NUTRITIONAL DISORDER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; CHEMICALLY INDUCED; HEMATOLOGIC NEOPLASMS; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; ANTINEOPLASTIC AGENTS; FEMALE; FERRIC COMPOUNDS; FRANCE; HEMATINICS; HEMATOLOGIC NEOPLASMS; HEMOGLOBINS; HUMANS; IRON; MALE; MALTOSE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84949084921     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2728-3     Document Type: Article

References (23)

1. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron. Ann Oncol 23:1954–1962
2. Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl 3):33–36
3. National Comprehensive Cancer Network Inc (2014) NCCN Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia - Version 2.2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive. Accessed 28 October 2014
4. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR (2010) American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116:4045–4059
5. Athibovonsuk P, Manchana T, Sirisabya N (2013) Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol 131:679–682
6. Dangsuwan P, Manchana T (2010) Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 116:522–525
7. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, Kim JH, Kim JW (2007) Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 105:199–204
8. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N (2013) Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 24:475–482
9. Hedenus M, Karlsson T, Ludwig H, Felder M, Roubert B, Birgegard G (2013) Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency. Blood 122:3439
10. Ludwig H, Muldur E, Endler G, Hubl W (2013) Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24:1886–1892
11. Cella D, Kallich J, McDermott A, Xu X (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15:979–986
12. Hudis CA, Van BS, Chang J, Muenstedt K (2004) rHuEPO and treatment outcomes: the clinical experience. Oncologist 9(Suppl 5):55–69
13. Brownlie T, Utermohlen V, Hinton PS, Haas JD (2004) Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 79:437–443
14. Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, Gasche C (2014) Evaluation of a Single Dose of Ferric Carboxymaltose in Fatigued, Iron-Deficient Women - PREFER a Randomized, Placebo-Controlled Study. PLoS One 9, e94217
15. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G (2011) Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 118:3222–3227
16. Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood TJ, Osterborg A, Rzychon B, Mitchell D, Beguin Y (2014) A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 22:2197–2206
17. Steinmetz HT, Tsamaloukas A, Schmitz S, Wiegand J, Rohrberg R, Eggert J, Breuer F, Tessen HW, Eustermann H, Thomas L (2010) A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 19:261–269
18. Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26:1611–1618
19. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12:231–242
20. Munoz M, Martin-Montanez E (2012) Ferric carboxymaltose for the treatment of iron-deficiency anemia. [corrected]. Expert Opin Pharmacother 13:907–921
21. Ludwig H, Van BS, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293–2306
22. Hentze MW, Muckenthaler MU, Galy B, Camaschella C (2010) Two to tango: regulation of Mammalian iron metabolism. Cell 142:24–38
23. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011–1023